Recent randomized studies on poly (adenosine diphosphate–ribose) polymerase inhibitors have demonstrated a substantial survival benefit in BRCA1/2 carriers [20–24], hence germline BRCA1/2 testing is becoming a mandatory in treatment decisions in advanced-stage ovarian cancer. Here, BRCA1 is linked to ovarian carcinoma.